Spironolactone and risk of upper gastrointestinal events: Association is unprovedBMJ 2006; 333 doi: http://dx.doi.org/10.1136/bmj.333.7566.501 (Published 31 August 2006) Cite this as: BMJ 2006;333:501
- Muhammad F Dawwas, clinical research fellow ([email protected])
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London WC2A 3PE
EDITOR—The study reported by Verhamme et al has several noteworthy limitations.1 Firstly, the mortality benefit conferred by spironolactone therapy in heart failure has been shown only among patients with severe disease2 and hence, as the authors acknowledged, such patients are far more likely to be prescribed this therapy than patients with, for example, relatively asymptomatic echocardiographic evidence of impaired left ventricular function. Given …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial